Table 1.
Human dermal fibroblasts reprogrammed to iPSC lines in direct comparative experiments using dbDNA and EBNA1 vectors
| Dermal fibroblast source | NCL developmental classification | Passage fibroblast number | Starting material | Time of cryopreservation |
|---|---|---|---|---|
| Normal | neonate | P32 | cryopreserved | <1 year |
| Normal | juvenile | P16 | cryopreserved | <1 year |
| Normal | juvenile | P9 | cryopreserved | <1 year |
| CLN3-A1 | juvenile | P3 | fresh | N/A |
| ∗CLN3-A2 | juvenile | P3 | fresh | N/A |
| CLN3-B | juvenile | P7 | fresh | N/A |
| CLN3-C | juvenile | P38 | cryopreserved | 12 years |
| CLN6-A | juvenile | P8 | cryopreserved | 15 years |
| CLN7-A | juvenile | P12 | cryopreserved | 15 years |
| CLN7-B | juvenile | P7 | cryopreserved | 15 years |
hDFs refractory to EBNA1-mediated iPSC reprogramming but successful with dbDNA. NCL, Neuronal ceroid lipofuscinosis.